港股異動 | 創科實業漲4.8% 獲多家投行唱好
格隆匯12月13日丨創科實業(0669.HK)現漲4.84%,報63.9港元,暫成交8395.1萬港元,最新總市值1169.4萬港元。高盛研報指,發表報告表示,預期全球無線工具將由目前佔比43%增至2021年之65%,相信創科(00669.HK)將受惠於上述趨勢及美國商業及住宅投資環境改善,因而帶動其全球市佔率由2018年12%提升至2021年度之14%,且2019年至2021年之每股盈利複合年增長率達21%。首予其“買入”評級,目標價為71.7港元。花旗研報指,調升公司2021年盈測1%以反映越南工廠效益下的毛利提升潛力,目標價由63港元升至70港元,予其“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.